Drug Profile
Research programme: fatty acid synthase inhibitors - FASgen
Alternative Names: C-75; FAS 093; FAS 115; FAS 20013; FAS 267; FAS 31; FAS 89B; FAS-031; FAS-247; FAS183; FAS57Latest Information Update: 17 Dec 2013
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer FASgen Inc
- Class
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Diabetes mellitus; Obesity; Tuberculosis
- Discontinued Stroke
Most Recent Events
- 17 Dec 2013 No development reported - Preclinical for Cancer in USA (PO)
- 17 Dec 2013 No development reported - Preclinical for Diabetes mellitus in USA (PO)
- 17 Dec 2013 No development reported - Preclinical for Obesity in USA (PO)